Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567387 | 0.87 | MAP2K1 (0.67) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 | |
| SCHEMBL2560087 | 0.86 | MAP2K1 (0.65) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2565002 | 0.85 | MAP2K1 (0.65) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 | |
| SCHEMBL29519571 | 0.83 | MAP2K1 (1.00) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 | |
| SCHEMBL2560400 | 0.83 | MAP2K1 (1.00) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 | |
| SCHEMBL2563441 | 0.81 | MAP2K1 (0.77) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 | |
| SCHEMBL2565695 | 0.80 | MAP2K1 (0.81) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 | |
| SCHEMBL2566005 | 0.80 | MAP2K1 (0.72) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 | |
| SCHEMBL2564197 | 0.80 | MAP2K1 (0.67) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2564919 | 0.80 | MAP2K1 (0.75) | MAP2K1CYP2C9KCNH2CYP2C19MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | MAP2K1 10/4885CYP2C9 3803/4885KCNH2 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.